Wu W H, Huo S J, Cheng C Y, Hong C J, Tsai S J
Division of Psychiatry, Cheng Hsin Rehabilitation and Medical Center, Veterans General Hospital-Taipei, Taiwan, ROC.
Neuropsychobiology. 2001;44(4):172-5. doi: 10.1159/000054938.
The serotonergic neurotransmitter system has been implicated in the pathogenesis of major depressive disorder (MDD). Of the 14 human serotonin (5-HT) receptors, the 5-HT(6) receptor may be a candidate for the study of MDD because of its relative abundance in certain limbic areas and its high affinity to several antidepressants. The present study tested the hypothesis that a 5-HT(6) genetic polymorphism (C267T) is associated with the clinical manifestations of, and/or antidepressant response in, MDD. The Hamilton Depression Rating Scale was used to assess 57 MDD patients before antidepressant treatment, with 34 patients completing the 4-week treatment and evaluation. The results of the association study provide that the 5-HT(6) C267T genetic variant does not play a major role in producing the clinical manifestations or antidepressant response for MDD patients. Further study with a functional 5-HT(6) polymorphism is needed to explore the role of 5-HT(6) in the pathogenesis of MDD.
血清素能神经递质系统与重度抑郁症（MDD）的发病机制有关。在14种人类血清素（5-HT）受体中，5-HT(6)受体可能是研究MDD的一个候选对象，因为它在某些边缘区域相对丰富，并且对几种抗抑郁药具有高亲和力。本研究检验了一个假设，即5-HT(6)基因多态性（C267T）与MDD的临床表现和/或抗抑郁反应相关。在抗抑郁治疗前，使用汉密尔顿抑郁量表对57例MDD患者进行评估，其中34例患者完成了为期4周的治疗和评估。关联研究结果表明，5-HT(6) C267T基因变异在MDD患者的临床表现或抗抑郁反应中不发挥主要作用。需要进一步研究功能性5-HT(6)多态性，以探索5-HT(6)在MDD发病机制中的作用。
